<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545142</url>
  </required_header>
  <id_info>
    <org_study_id>031-KOB-0701</org_study_id>
    <nct_id>NCT00545142</nct_id>
  </id_info>
  <brief_title>Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness</brief_title>
  <acronym>SMART-A</acronym>
  <official_title>Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy and safety of co-administration of Abilify(aripiprazole) with
      Depakote(divalproate) in the acute phase of 6-week treatment of acute mania in patients with
      bipolar disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Further study details as provided by Korea OIAA
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the YMRS total score from baseline to the end of 6-week study</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in YMRS total scores from baseline to the end of 6-week study</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abilify(Aripiprazole)</intervention_name>
    <description>co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depakote(Divalproate)</intervention_name>
    <description>co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria:

          1. Mania or mixed episode of Bipolar disorder Bipolar disorder, mania or mixed episode
             according to DSM-IV

          2. The periods of mania or mixed episode should be within 3 months, and YMRS score at
             enrollment be more than 20.

          3. Male and female between the age of 18 and 65 (In case of child-bearing women, negative
             pregnancy test results should be confirmed before the administration of the
             investigational drug and appropriate contraception be used. Pregnant and
             breast-feeding women cannot be included)

          4. Patients who can consent to participate in this clinical trial

          5. Patients who understand this trial and comply with all protocol requirements

        Exclusion Criteria:

          1. Patients with the following clinical symptoms diagnosed using DSM-IV:

               -  Delirium, dementia, amnestic or other cognitive disorders

               -  Schizophrenia or schizoaffective disorder

          2. Patients who do not respond to clozapine

          3. Patients who are expected to require the administration of prohibited concomitant
             drugs during the clinical trial period

          4. Patients diagnosed with substance-related disorder according to DSM-IV within the past
             3 months (abuse, intoxication, dependency and/or withdrawal symptoms). The abuse of
             benzodiazepines is included with the exception of caffeine or nicotine.

          5. Patients known to have allergy or hypersensitivity reaction to Ablify(aripiprazole) or
             other quinolinones

          6. Patients at high risk of suicide attempt or with the history of murder or mental
             status test

          7. Patients with the history of neuroleptic malignant syndrome

          8. Patients with the past history which may cause serious adverse events that can affect
             the safety or efficacy evaluation during the clinical trial period

          9. Patients with vital sign or ECG results in the clinically significant abnormal
             laboratory test Patients with clinically significantly abnormal laboratory results,
             vital sign or ECG results

         10. Pregnant women or child-bearing women who do not or cannot use appropriate
             contraception

         11. Patients given psychotropic medications (except benzodiazepines) one day before
             baseline visit

         12. Patients treated with Fluoxetine for the last 4 weeks

         13. Patients who participated in clinical trials with other investigational drugs for the
             last one month

         14. Patients with the history of convulsive disorder

         15. Patients with the history of more than 4 mood episodes each year (rapid cycling)
             during the last 2 years prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won-Myong Bahk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Mary's Hospital, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <last_update_submitted>June 24, 2010</last_update_submitted>
  <last_update_submitted_qc>June 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jeong, Yonghui</name_title>
    <organization>Korea Otsuka Pharmaceutical Co.,Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

